As studies have reported the important role of CDK4 signal pathway in the development of resistance to target therapy in other malignancies (Yadav et al., 2014; Goel et al., 2016), we next examined the roles of CDK4-RB pathway in sunitinib resistance in RCC cells. This evidence concerns the gene RB1 and renal cell carcinoma.